Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes

Oncogene

Volumn 34, Issue 3, 2015, Pages 319-333

  Webber, J P ^a   Spary, L K ^a   Sanders, A J ^a   Chowdhury, R ^a   Jiang, W G ^a   Steadman, R ^a   Wymant, J ^a   Jones, A T ^a   Kynaston, H ^a   Mason, M D ^a   Tabi, Z ^a   Clayton, A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Exosomes; Fibroblast; Prostate; Stroma; TGF

Indexed keywords

HEPARAN SULFATE; RAB PROTEIN; RAB27A PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; EXOSOME; GENE SILENCING; GENETICS; HUMAN; IMMUNOBLOTTING; MALE; METABOLISM; MYOFIBROBLAST; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; STROMA CELL; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; EXOSOMES; GENE KNOCKDOWN TECHNIQUES; HEPARITIN SULFATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE, NUDE; MYOFIBROBLASTS; PROSTATIC NEOPLASMS; RAB GTP-BINDING PROTEINS; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84925446437     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.560     Document Type: Article

References (43)

1. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 2007; 38: 1611-1620.
2. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci 2010; 107: 20009-20014.
3. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
4. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62: 6021-6025.
5. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer. Clin Cancer Res 2002; 8: 2912-2923.
6. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al. A stromarelated gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
7. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 2012; 38: 307-313.
8. Mesker WE, Liefers G-J, Junggeburt JMC, van Pelt GW, Alberici P, Kuppen PJK et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 2009; 31: 169-178.
9. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh I-T, Sun L-Z. Transforming growth factor-β signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res 2007; 67: 5737-5746.
10. Renzoni E, Abraham D, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G et al. Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res 2004; 5: 24.
11. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Path 2012; 180: 1340-1355.
12. Webber J, Steadman R, Tabi Z, Mason MD, Clayton A. Cancer exosomes activate fibroblast to myofibroblast differentiation in a TGFβ dependent manner. Cancer Res 2010; 70: 9621-9630.
13. Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS One 2012; 7: e52465.
14. Raposo G, Nijman HW, Stoorvogel W, Leijendekker R, Harding CV, Melief CJM et al. B Lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-1172.
15. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319: 1244-1247.
16. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Exp Rev Proteomics 2009; 6: 267-283.
17. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
18. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-593.
19. Junji W, Hideya O, Hiroyuki S, Akio Y, Shuntaro N, Takashi M et al. Surface-bound TGF-b on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-Cells in malignant effusions. Anticancer Res 2010; 30: 3747-3757.
20. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumorderived exosomes down-modulate NKG2D expression. J Immunol 2008; 180: 7249-7258.
21. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Res 2007; 67: 7458-7466.
22. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011; 71: 3792-3801.
23. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 2012; 18: 883-891.
24. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 2010; 116: 2385-2394.
25. Gesierich S, Berezovskiy I, Ryschich E, Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 2006; 66: 7083-7094.
26. Hood JL, Pan H, Lanza GM, Wickline SA. Paracrine induction of endothelium by tumor exosomes. Lab Invest 2009; 89: 1317-1328.
27. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosomeinduced endothelial cell activation. Cancer Res 2010; 70: 1668-1678.
28. Richman PI, Tilly R, Jass JR, Bodmer WF. Colonic pericrypt sheath cells: characterisation of cell type with new monoclonal antibody. J Clin Pathol 1987; 40: 593-600.
29. Hetheridge C, Mavria G, Mellor H. Uses of the in vitro endothelial-fibroblast organotypic co-culture assay in angiogenesis research. Biochem Soc Trans 2011; 39: 1597-1600.
30. Lories V, Cassiman JJ, Van den Berghe H, David G. Multiple distinct membrane heparan sulfate proteoglycans in human lung fibroblasts. J Biol Chem 1989; 264: 7009-7016.
31. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-2223.
32. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133(Pt 8): 2232-2247.
33. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9: 1545-1564.
34. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488.
35. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010; 12: 19-30.
36. Massague J. Receptors for the TGF-beta family. Cell 1992; 69: 1067-1070.
37. Mitchell JP, Court J, Mason MD, Tabi Z, Clayton A. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. J Immunol Methods 2008 ; 335: 98-105.
38. Lamparski H, Metha-Damani A, Yao J, Patel S, Hsu D, Ruegg C et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270: 211-226.
39. Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J et al. Proteomic analysis of bladder cancer exosomes. Mol Cell Proteomics 2010; 6: 1324-1338.
40. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011; 187: 676-683.
41. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406-3415.
42. Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O. Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med 2006; 18: 981-986.
43. Webber J, Meran S, Steadman R, Phillips A. Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem 2009; 284: 9083-9092.